Chapter 2 Global Market for Anti-obesity Drugs (PHM281A)
- Anti-obesity Drugs
- Study Goals and Objectives
- Reasons for Doing this Study
- Scope of Report
- Market Outlook
- Market Summary
- Market Overview of Anti-obesity Drugs
- Definitions of Adult Obesity and Overweight
- Rising Prevalence of Obesity
- Impact of Obesity on Global Economy
- Increasing Awareness Regarding Obesity
- Global Market for Anti-obesity Drugs, by Type
- Prescription Drugs
- Over-the-Counter Anti-obesity Drugs
- Global Market for Anti-obesity Drugs, by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Market for Anti-obesity Drugs, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
- ESG Developments of Anti-obesity Drugs
- Importance of ESG in Anti-obesity Drugs Industry
- ESG Pillars in the Anti-obesity Drug Industry
- ESG Ratings and Metrics: Understanding the Data
- ESG Practices in the Anti-obesity Drug Industry
- Concluding Remarks
Chapter 3 Drugs of Abuse Testing: Technologies and Global Markets (PHM013J)
- Drugs of Abuse Testing
- Study Goals and Objectives
- Reasons for Doing This Study
- Scope of Report
- Summary and Highlights
- Market and Technology Background of Drugs of Abuse Testing
- Overview
- Testing Technologies
- Single Tests vs. Multiparameter Tests
- DOA Screening
- Porter’s Five Forces Analysis of Drugs of Abuse Testing
- Market Dynamics of Drugs of Abuse Testing
- Market Drivers
- Market Restraints
- Market Opportunities
- Regulatory Scenario of Drugs of Abuse Testing
- North America
- South America
- Central America and the Caribbean
- Europe
- Asia-Pacific
- Global Drugs of Abuse Testing Market, by Drug Type
- Alcohol
- Amphetamine and Methamphetamine
- Cannabis/Marijuana
- Cocaine
- Opioids
- Others
- Global Drugs of Abuse Testing Market, by End User
- Drug Testing Laboratories
- Hospitals
- Workplaces
- Others
- Market Breakdown of Drugs of Abuse Testing, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)
Chapter 4 Global Markets for Bioengineered Protein Drugs (BIO009H)
- Bioengineered Protein Drugs
- Study Goals and Objectives
- Scope of This Report
- Market Summary
- Market and Technology Background of Bioengineered Protein Drugs
- Protein Drugs Overview
- Bioengineered Protein Drugs
- Manufacturing Technologies of Bioengineered Protein Drugs
- Fractionation/Extraction from Natural Sources (Human/Animal)
- Microbial Fermentation and Bioreactors
- Transgenics
- Mammalian Cell Culture
- Market Dynamics of Bioengineered Protein Drugs
- Market Driver
- Market Challenges
- Market Breakdown of Bioengineered Protein Drugs by Drug Type
- Overview
- Monoclonal Antibodies (mAbs)
- Peptide Hormones
- Vaccines
- Fusion Proteins
- Blood Factors
- Peptide Antibiotics
- Cytokines
- Therapeutic Enzymes
- Market Breakdown of Bioengineered Protein Drugs, by Disease
- Overview
- Market Breakdown of Bioengineered Protein Drugs, by Region
- North America Market Revenue, by Drug Type
- Europe Market Revenue, by Drug Type
- Emerging Markets Revenue, by Drug Type
- Regulatory Aspects and New Approvals of Bioengineered Protein Drugs Market
- New Approvals
- Emerging Trends/Upcoming Technologies in the Market
- Bi- and Multi-Specific Antibodies
- Key Trends in Biopharmaceutical Industry
Chapter 5 Global Market for Pain Management Drugs and Devices (HLC026G)
- Pain Management Drugs and Device
- Study Goals and Objectives
- Reasons for Doing this Study
- Scope of Report
- Market Outlook
- Market Summary
- Highlights of the Market for Pain Management Drugs and Devices
- Market Overview of Pain Management Drugs and Device
- History of Pain and Pain Treatment
- The Perception of Pain
- Types of Pain
- Assessment of Pain
- How Pain is Diagnosed
- How Pain is Treated
- Market Dynamics of Pain Management Drugs and Device
- Market Drivers
- Market Restraints
- Market Challenges
- Market Breakdown of Pain Management Drugs and Device, by Product
- Pharmaceuticals
- Pain Management Devices
- Market Breakdown of Pain Management Drugs and Device, by Application
- Musculoskeletal Pain
- Post-operative Pain
- Neuropathic Pain
- Cancer Pain
- Migraine/Headache
- Other Applications
- Market Breakdown of Pain Management Drugs and Device, by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
- ESG Development of Pain Management Drugs and Device
- Introduction to ESG
- Sustainability in the Pain Management Drugs and Devices Industry: An ESG Perspective
- Case Study
- Concluding Remarks
- Emerging Technologies of Pain Management Drugs and Device
- Overview
- Technology Advancements in Opioid Drugs
- Technology Advancements in Non-narcotic Drugs
- Technology Advancements in Neuromodulation Devices
- Technology Advancements in Infusion Pumps
- Trends in Pain Management
List of Tables
Table 1: Global Market for Anti-obesity Drugs, by Distribution Channel, Through 2028
Table 2: Definitions of Adult Obesity and Overweight
Table 3: Number of People, Aged Over 5 Years, and Percentage of the Population With Overweight or Obesity, 2020-2035
Table 4: Global Obesity Trends for Children and Adolescents, Aged 5 to 19 Years, by Gender, 2020-2035
Table 5: Global Obesity Trends for Adults, Aged 20 Years and Above, by Gender, 2020-2035
Table 6: Global Economic Impact of High BMI (BMI =25kg/m²), 2020-2035
Table 7: Global Market for Anti-obesity Drugs, by Drug Type, Through 2028
Table 8: Global Market for Anti-obesity Drugs, by Distribution Channel, Through 2028
Table 9: Global Market for Anti-obesity Drugs, by Region, Through 2028
Table 10: ESG Ratings and Metrics of Anti-obesity Drugs
Table 11: Environmental Performance of Anti-obesity Drugs
Table 12: Social Performance of Anti-obesity Drugs
Table 13: Governance Performance of Anti-obesity Drugs
Table 14: ESG Rankings for Major Anti-obesity Drug Companies, 2023*
Table 15: Global Market for Drugs of Abuse Testing, by Region, Through 2027
Table 16: Cutoff Concentrations for Initial and Confirmatory Drug Tests in Urine
Table 17: Deaths from Tobacco, Alcohol and Drugs, Across Countries, 2019
Table 18: Commonly Abused Drugs
Table 19: Prevalence of Drug Use in General, Population Across Region, 2020
Table 20: Global Drug Seizure, by Drug Type, 2020
Table 21: U.S. Drug Testing Legislation, by State, 2017
Table 22: European Drug Testing Legislation, by Country
Table 23: Global Market for Drugs of Abuse Testing, by Region, Through 2027
Table 24: Global Market for Bioengineered Protein Drugs, by Drug Type, Through 2027
Table 25: Characteristics of Large Molecule/Protein Drugs
Table 26: Bioengineered Protein Drugs vs. Chemically Synthesized Drugs
Table 27: Selected Protein Drugs Made, by Fractionation
Table 28: Selected Therapeutic Drugs Produced, by Microbial Fermentation
Table 29: Selected Protein Drugs Produced, by Transgenic Animals, Plants, and Microorganisms
Table 30: Selected Protein Drugs Made, by Cell Culture
Table 31: Number and Distribution of Persons Aged 60+, by Region, 2019 and 2050
Table 32: Global Pipeline Molecules, by Type, Through 2021
Table 33: Global Market for Bioengineered Protein Drugs, by Drug Type, Through 2027
Table 34: Percentage of Major Proteins Present in Different Fractions After Cohn’s Fractionation Method
Table 35: Global Market for Bioengineered Protein Drugs, by Disease, Through 2027
Table 36: Global Market for Bioengineered Protein Drugs, by Region, Through 2027
Table 37: Newly Approved Monoclonal Antibodies (mAbs), January 2021-December 2022
Table 38: Newly Approved Peptide Hormones and Drugs, January 2021-December 2022
Table 39: Newly Approved Vaccines, January 2021-December 2022
Table 40: Vaccine Candidates in Clinical Phase, January 2021-December 2022
Table 41: Newly Approved Blood Factors, January 2021-December 2022
Table 42: Newly Approved Peptide Antibiotics, January 2021-December 2022
Table 43: Newly Approved Therapeutic Enzymes, January 2021-December 2022
Table 44: Newly Approved Cytokines, January 2021-December 2022
Table 45: Newly Approved Fusion Protein, January 2021-December 2022
Table 46: Selected Bi-Specific Antibodies in Phase 3 Clinical Trials, 2023
Table 47: Global Market for Pain Management Drugs and Devices, by Product, Through 2028
Table 48: Global Market for Pain Management Drugs and Devices, by Region, Through 2028
Table 49: Objective Signs of Pain
Table 50: Prevalence of Chronic Pain in Older Adults, by Site
Table 51: Opioid Lawsuit Settlements
Table 52: Global Market for Pain Management Drugs and Devices, by Product, Through 2028
Table 53: FDA Pain Management Drug Approvals, 2020-2023
Table 54: Pain Management Major Drugs, by Company
Table 55: Emerging Pain Therapeutics
Table 56: Global Market for Pain Management Pharmaceuticals, by Product, Through 2028
Table 57: Global Market for Pain Management Devices, by Type, Through 2028
Table 58: Global Market for Pain Management Drugs and Devices, by Application, Through 2028
Table 59: Cumulative Volumes of Hip and Knee Procedures, 2012-2021
Table 60: Neuropathic Pain Medication
Table 61: Cancer Pain Medication
Table 62: Global Market for Pain Management Drugs and Devices, by Region, Through 2028
Table 63: ESG Ranking of Major Pharma Players for Pain Therapeutics, 2022
Table 64: ESG Rankings for Major Pain Management Drug and Device Companies, 2023*
Table 65: ESG: Environmental Overview
Table 66: ESG: Social Overview
Table 67: ESG: Governance Overview
List of Figures
Figure 1: Global Market for Anti-obesity Drugs, by Distribution Channel, 2021-2028
Figure 2: Global Market for Anti-obesity Drugs, by Drug Type, 2021-2028
Figure 3: Global Market for Anti-obesity Drugs, by Distribution Channel, 2021-2028
Figure 4: Global Market Shares of Anti-obesity Drugs, by Region, 2021-2028
Figure 5: Global Market Shares of Drugs of Abuse Testing, by Region, 2021
Figure 6: Annual Self-reported Alcohol-impaired Driving Episodes Among U.S. Adults, 2010-2020
Figure 7: Legal Adult-Use Cannabis Sales Worldwide, 2020-2025*
Figure 8: Global Market Shares of Drugs of Abuse Testing, by Region, 2021
Figure 9: Global Market for Bioengineered Protein Drugs, by Drug Type, 2019-2027
Figure 10: Global Market Shares of Bioengineered Protein Drugs, by Drug Type, 2021
Figure 11: Global Market Shares of Bioengineered Protein Drugs, by Disease, 2021
Figure 12: Snapshot of Global Market for Bioengineered Protein Drugs, by Region
Figure 13: Global Market Shares of Bioengineered Protein Drugs, by Region, 2021
Figure 14: NDAs and BLA Approvals in Market for Bioengineered Protein Drugs, by Drug Type, 2021 and 2022
Figure 15: Share of NDAs and BLA Approvals in Market for Bioengineered Protein Drugs, by Drug Type, 2021 and 2022
Figure 16: Global Market for Pain Management Drugs and Devices, by Product, 2020-2028
Figure 17: Global Market for Pain Management Drugs and Devices, by Region, 2020-2028
Figure 18: Pain Management Techniques
Figure 19: Pain Management Drugs and Devices: Market Dynamics
Figure 20: Common Chronic Pain: Reasons
Figure 21: Cancer Incidence, by Region, 2020 vs. 2040
Figure 22: Percentage of Global Population Above 65 Years, 2018-2022
Figure 23: Global Market Shares of Pain Management Drugs and Devices , by Product, 2022
Figure 24: Global Market Shares of Pain Management Pharmaceuticals, by Product, 2022
Figure 25: Global Market Shares of Pain Management Devices, by Type, 2022
Figure 26: Global Market Shares of Pain Management Drugs and Devices, by Application, 2022
Figure 27: Classification of Neuropathic Pain
Figure 28: Causes of Cancer Pain
Figure 29: Burn Pain Management Approach
Figure 30: Global Market Shares of Pain Management Drugs and Devices, by Region, 2022
Figure 31: ESG Pillars
Figure 32: Advantages of ESG for Companies
Figure 33: ESG-Adoption Level across Industries
Figure 34: Hospitals: Sustainability Priorities
Figure 35: Novartis: ESG Rating
Figure 36: Novartis: Major ESG Activities, 2022
